Pular para o conteúdo

#37 ME/CFS breakthroughs: are treatments getting closer? With ActionForME, NIH, CODA, Bateman Horne Center & PrecisionLife

26 de junho de 2026 · 60 min

Notas do episódio

SCIENCE: Are ME/CFS research breakthroughs finally helping us understand the disease and move closer to treatments?

ME/CFS has been underfunded and under-researched for decades. Despite the scale and severity of the illness, major gaps remain in diagnosis, clinical care and treatment options.

Part of the challenge is scientific. ME/CFS is a complex, multi-system illness that can affect the immune system, nervous system, metabolism and energy production. There is still no single diagnostic biomarker, and people who are more severely affected are often left out of research because participation itself can be difficult or impossible.

People with ME/CFS, advocates, clinicians and researchers have fought to move the field forward but progress has been frustratingly slow. Now, in the wake of Long Covid and growing recognition of infection associated conditions the needle may be finally shifting.

In this episode we bring together leading voices in ME/CFS research, advocacy and clinical innovation to ask: what breakthroughs are changing our understanding of ME/CFS, and could they bring us closer to better diagnostics, treatment strategies and care?


Across these conversations, several themes emerge:

  • How Long Covid has brought funding, research infrastructure, and clinical attention to ME/CFS
  • Why genetics research, including DecodeME and LOCOME studies are key milestones that could enable individualised treatment
  • How precision medicine could enable personalised medicine
  • How collaboration between organisations is accelerating progress
  • Why a major gap remains between research momentum and the reality of patient care today

Dr Vicky Whittemore is programme director of the NINDs at the NIH, overseeing the ME/CFS grant portfolio. She has brought her decades of expertise to identify infrastructure gaps (biobanks, training, data sharing), and produce a full research roadmap focused not on describing ME/CFS but on getting treatments into clinical trials and to the patients.

Amy Rochlin is CEO of the Complex Disorders Alliance (CODA), a patient-founded non-profit organisation accelerating groundbreaking research, clinical innovation, and patient-centred solutions for complex disorders. Through collaborations with industry and clinical leaders they are pushing to develop diagnostic tools and targeted therapies through collaboration and precision medicine at scale. They have recently announced a multi-system research model for complex disease.

Tahlia Ruschioni is the Executive Director of the Bateman Horne Center, where she has led the transformative growth of the Medical Education Resource Center (MERC) as a global model for clinician education and training in post-infectious disease care, reaching more than 13,000 healthcare professionals across 90 countries and 46 U.S. states, offering accredited medical education in the clinical management of complex, multisystem illnesses. She led the development and launch of the BHC Clinical Care Guide which provides an actionable roadmap for clinicians of ME/CFS, Long Covid and Infection-Associated Chronic Conditions.

Sonya Chowdhury, CEO of Action for ME has seen a palpable shift over her 14 years tenure, position the non-profit at the forefront of the joining patient experience with science. Co-lead of the DecodeME study (alongside the University of Edinbugh), Action for ME has evolved to be a driving force of the research, building the Genetics Centre for Excellence, identifying patients’ top 10+ research priorities, and giving focus to PEM in their PRIME workshops.

Dr Steve Gardner, CEO and co-founder of PrecisionLife has built on the incredible work of Decode ME and the wealth of patient data to build clear understanding of the genes involved in ME/CFS. Their work has identified 260 associated genes which has lead to 42 drug repurposing candidates, and the potential to finally offer the stratification and individualise treatment that the community has been needing.

David Tuller is a senior fellow in public health and journalism at UC Berkeley's Center for Global Public Health who has been investigating scientific, methodological and ethical problems within ME/CFS since finding errors in the 2011 PACE trial. His advocacy work, documented in his ongoing series Trial By Error, was an important voice in finally overturning the NICE guidelines of treating ME/CFS with their admission of Graded Exercise Therapy being harmful and Cognitive Behavioural Therapy not curative.

Interested in taking part or sharing feedback on Make Visible? Please click here.

Find it easier to read than listen? Download the transcript here.

Make Visible

@visible.health

[email protected]

Todos os episódios de Make Visible: ME/CFS, Long Covid, POTS, EDS, Fibro & MCAS Explored

Configurações

Exibição

Idioma

Define quais estações você vê primeiro na página inicial.

Histórico

As rádios e episódios ouvidos recentemente e suas últimas buscas ficam só neste navegador.

Avisos

Um aviso rápido quando um podcast que você segue tem um episódio novo. Desative podcasts individuais pelo sino na página deles.

Conta

Salve favoritos – no app e no site.

Atalhos de teclado

/
Abrir busca
Espaço
Reproduzir ou pausar
← →
No player: voltar 15 s, avançar 30 s (episódios) · na fileira: próximo bloco
↑ ↓
Na fileira: alvo dentro do bloco
Home / End
Na fileira: primeiro ou último bloco
Esc
Fechar janela ou menu
?
Esta visão geral
Tocando agora

Ir para a estação

A seguir

    Adicione episódios com “A seguir” – eles tocam depois do episódio atual.